ATE406797T1 - Exo-s-mecamylamin-formulierung - Google Patents
Exo-s-mecamylamin-formulierungInfo
- Publication number
- ATE406797T1 ATE406797T1 AT05024899T AT05024899T ATE406797T1 AT E406797 T1 ATE406797 T1 AT E406797T1 AT 05024899 T AT05024899 T AT 05024899T AT 05024899 T AT05024899 T AT 05024899T AT E406797 T1 ATE406797 T1 AT E406797T1
- Authority
- AT
- Austria
- Prior art keywords
- exo
- mecamylamine
- pharmaceutically acceptable
- disorder
- amount
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960002525 mecamylamine Drugs 0.000 abstract 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000005586 smoking cessation Effects 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010020802 Hypertensive crisis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000000923 atherogenic effect Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000008559 autonomic dysreflexia Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003368 psychostimulant agent Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 230000003033 spasmogenic effect Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11253498P | 1998-12-16 | 1998-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406797T1 true ATE406797T1 (de) | 2008-09-15 |
Family
ID=22344414
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05024899T ATE406797T1 (de) | 1998-12-16 | 1999-12-16 | Exo-s-mecamylamin-formulierung |
| AT99967401T ATE320711T1 (de) | 1998-12-16 | 1999-12-16 | Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99967401T ATE320711T1 (de) | 1998-12-16 | 1999-12-16 | Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20020016370A1 (de) |
| EP (3) | EP1139744A4 (de) |
| JP (5) | JP2002532393A (de) |
| AT (2) | ATE406797T1 (de) |
| AU (2) | AU2368200A (de) |
| CA (2) | CA2393442A1 (de) |
| CY (1) | CY1108577T1 (de) |
| DE (2) | DE69939498D1 (de) |
| DK (2) | DK1139743T3 (de) |
| ES (2) | ES2313187T3 (de) |
| PT (2) | PT1139743E (de) |
| WO (2) | WO2000035279A1 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| ATE359075T1 (de) | 2002-12-20 | 2007-05-15 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
| US20070224284A1 (en) | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| EP1603544B1 (de) * | 2003-03-14 | 2007-10-10 | AGI Therapeutics Research Limited | Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo¬2.2.1|heptan-2-amine |
| DE10318714B4 (de) * | 2003-04-25 | 2006-03-23 | Hf Arzneimittelforschung Gmbh | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| JP2009519962A (ja) * | 2005-12-19 | 2009-05-21 | コメンティス，インコーポレーテッド | 眼投与用局所メカミルアミン製剤およびその使用 |
| JP5694645B2 (ja) | 2006-03-16 | 2015-04-01 | ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ | 改善された嗅ぎたばこ組成物 |
| EP2086541A4 (de) * | 2006-10-09 | 2011-06-22 | Glaxosmithkline Llc | Zusammensetzungen zur reduzierung von nikotinentzugssymptomen und/oder tabakverbrauch |
| US20090018407A1 (en) * | 2007-03-30 | 2009-01-15 | Searete Llc, A Limited Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242951A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
| US20080319276A1 (en) * | 2007-03-30 | 2008-12-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242952A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Effective response protocols for health monitoring or the like |
| US20090005653A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242949A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242947A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Configuring software for effective health monitoring or the like |
| US20090119154A1 (en) * | 2007-11-07 | 2009-05-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content |
| US20080243005A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20090005654A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242948A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
| EP2322168A1 (de) * | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen |
| US8569381B2 (en) | 2008-05-23 | 2013-10-29 | Targacept, Inc. | Combination therapy for the management of hypertension |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| WO2011008686A1 (en) * | 2009-07-14 | 2011-01-20 | Targacept, Inc. | Exo-s-mecamylamine method, use, and compound for treatment |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| RU2582339C2 (ru) | 2010-05-27 | 2016-04-27 | Таргасепт, Инк. | Неконкурентные антагонисты никотиновых рецепторов |
| AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| JP5681819B2 (ja) | 2011-02-11 | 2015-03-11 | バットマーク・リミテッド | 吸入器コンポーネント |
| EP2729148A4 (de) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson |
| CA2839099C (en) | 2011-09-06 | 2016-06-28 | British American Tobacco (Investments) Limited | Heating smokeable material |
| KR102196418B1 (ko) | 2011-09-06 | 2020-12-30 | 니코벤처스 트레이딩 리미티드 | 가열식 끽연 가능 물질 |
| AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| WO2013142162A1 (en) * | 2012-03-23 | 2013-09-26 | Targacept, Inc. | Method of treating bladder disorders |
| GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
| GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2504075A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
| GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
| GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
| CN106999449B (zh) | 2014-08-22 | 2021-04-02 | 阿塔卡马治疗股份有限公司 | 用于治疗多汗症的方法 |
| GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| JP2018511127A (ja) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 渇望入力及び支援システム |
| GB201505595D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Cartridge for use with apparatus for heating smokeable material |
| GB201505597D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Article for use with apparatus for heating smokable material |
| GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
| US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
| US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
| MY192211A (en) | 2016-04-27 | 2022-08-08 | Nicoventures Trading Ltd | Electronic aerosol provision system and vaporizer therefor |
| EP3565617A1 (de) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Vorrichtungen und verfahren zur transdermalen wirkstofffreisetzung |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| GB202203728D0 (en) * | 2022-03-17 | 2022-05-04 | Univ Oxford Innovation Ltd | Treatments and methods for increasing dopamine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
| US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
| EP0579260A1 (de) * | 1987-07-07 | 1994-01-19 | Beecham Group Plc | Verwendung eines Vasodilators zur Behandlung von pulmonalem Bluthochdruck und/oder Rechtsherzversagen relatierten Krankheiten |
| US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1999
- 1999-12-16 DE DE69939498T patent/DE69939498D1/de not_active Expired - Lifetime
- 1999-12-16 ES ES05024899T patent/ES2313187T3/es not_active Expired - Lifetime
- 1999-12-16 WO PCT/US1999/030153 patent/WO2000035279A1/en not_active Ceased
- 1999-12-16 AT AT05024899T patent/ATE406797T1/de active
- 1999-12-16 AU AU23682/00A patent/AU2368200A/en not_active Abandoned
- 1999-12-16 JP JP2000587609A patent/JP2002532393A/ja not_active Withdrawn
- 1999-12-16 EP EP99967396A patent/EP1139744A4/de not_active Withdrawn
- 1999-12-16 EP EP99967401A patent/EP1139743B1/de not_active Expired - Lifetime
- 1999-12-16 CA CA002393442A patent/CA2393442A1/en not_active Abandoned
- 1999-12-16 ES ES99967401T patent/ES2260959T3/es not_active Expired - Lifetime
- 1999-12-16 DE DE69930552T patent/DE69930552T2/de not_active Expired - Lifetime
- 1999-12-16 DK DK99967401T patent/DK1139743T3/da active
- 1999-12-16 EP EP05024899A patent/EP1634498B1/de not_active Expired - Lifetime
- 1999-12-16 JP JP2000587608A patent/JP2002532392A/ja active Pending
- 1999-12-16 AU AU23686/00A patent/AU2368600A/en not_active Abandoned
- 1999-12-16 DK DK05024899T patent/DK1634498T3/da active
- 1999-12-16 WO PCT/US1999/030137 patent/WO2000035280A1/en not_active Ceased
- 1999-12-16 PT PT99967401T patent/PT1139743E/pt unknown
- 1999-12-16 AT AT99967401T patent/ATE320711T1/de active
- 1999-12-16 PT PT05024899T patent/PT1634498E/pt unknown
- 1999-12-16 CA CA002393437A patent/CA2393437C/en not_active Expired - Fee Related
-
2001
- 2001-06-15 US US09/882,934 patent/US20020016370A1/en not_active Abandoned
-
2008
- 2008-11-19 CY CY20081101333T patent/CY1108577T1/el unknown
-
2011
- 2011-03-14 JP JP2011055716A patent/JP2011126909A/ja not_active Withdrawn
-
2013
- 2013-12-13 JP JP2013258032A patent/JP2014051528A/ja active Pending
-
2016
- 2016-01-25 JP JP2016011658A patent/JP2016065108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE320711T1 (de) | 2006-04-15 |
| PT1139743E (pt) | 2006-06-30 |
| ES2260959T3 (es) | 2006-11-01 |
| JP2011126909A (ja) | 2011-06-30 |
| JP2002532392A (ja) | 2002-10-02 |
| JP2016065108A (ja) | 2016-04-28 |
| EP1139744A1 (de) | 2001-10-10 |
| EP1139743B1 (de) | 2006-03-22 |
| EP1139743A1 (de) | 2001-10-10 |
| DE69930552D1 (de) | 2006-05-11 |
| EP1139744A4 (de) | 2003-01-02 |
| WO2000035279A1 (en) | 2000-06-22 |
| PT1634498E (pt) | 2008-10-28 |
| EP1634498B1 (de) | 2008-09-03 |
| CY1108577T1 (el) | 2014-04-09 |
| EP1139743A4 (de) | 2003-01-02 |
| CA2393437A1 (en) | 2000-06-22 |
| CA2393437C (en) | 2009-12-15 |
| DK1634498T3 (da) | 2008-12-15 |
| AU2368600A (en) | 2000-07-03 |
| JP2014051528A (ja) | 2014-03-20 |
| JP2002532393A (ja) | 2002-10-02 |
| DE69930552T2 (de) | 2006-11-30 |
| WO2000035280A1 (en) | 2000-06-22 |
| CA2393442A1 (en) | 2000-06-22 |
| DK1139743T3 (da) | 2006-07-31 |
| US20020016370A1 (en) | 2002-02-07 |
| DE69939498D1 (de) | 2008-10-16 |
| AU2368200A (en) | 2000-07-03 |
| EP1634498A2 (de) | 2006-03-15 |
| EP1634498A3 (de) | 2006-03-29 |
| ES2313187T3 (es) | 2009-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406797T1 (de) | Exo-s-mecamylamin-formulierung | |
| PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
| BR0206559A (pt) | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto | |
| ATE253039T1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
| WO2002043652A3 (en) | Anti-proliferative drugs | |
| JP2002532392A5 (de) | ||
| MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
| Summers et al. | THA—a review of the literature and its use in treatment of five overdose patients | |
| ATE433959T1 (de) | Analoge von kokain | |
| SE7910501L (sv) | Lekemedel for behandling av det centrala nervsystemet | |
| DK1212060T3 (da) | Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom | |
| BRPI0506881A (pt) | derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo | |
| ES2187646T3 (es) | Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes. | |
| Durant et al. | Comparison of the neuromuscular blocking properties of Org NC 45 and pancuronium in the rat, cat and rhesus monkey | |
| NO984564L (no) | FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister | |
| Feinberg et al. | Methadone and schizophrenia. | |
| Dere et al. | NMDA-receptor antagonism via dextromethorphan and ifenprodil modulates graded anxiety test performance of C57BL/6 mice | |
| NZ224502A (en) | Silyl alkylene amines and pharmaceutical use, methods for preparation and the treatment of non humans | |
| Mison-Crighel et al. | Glutaminase activity and neocortical excitability | |
| Messer et al. | Synthesis, biochemical activity and behavioral effects of a series of 1, 4, 5, 6-tetrahydropyrimidines as novel ligands for M1 receptors | |
| KR920000717A (ko) | 디클로로아닐린 화합물 | |
| RU2192275C2 (ru) | Способ лечения опийной наркомании | |
| WO2003007966A1 (de) | Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit | |
| Ajit et al. | Illicit Drugs and their Assessment: A Brief Review | |
| Middleton Jr et al. | Immediate Hypersensitivity: II. Drugs in Clinical Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1634498 Country of ref document: EP |